Treprostinil benefits PAH patients with cardiovascular issues

PHA Canada
Feb 4, 2025
1 min read

Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new analysis of data from two clinical trials indicated that treprostinil (Remodulin) in addition to existing treatment was safe and effective in preventing clinical worsening for these patients.

Read the CHEST journal article here

Recent Posts

Start up: Supporting PAH patients beginning prostanoids

This study looked at a French support program designed to help people with pulmonary arterial hypertension (PAH) start and adjust their dose of selexipag. Nurses called patients three days after patie

Sotatercept vs. selexipag in severe PAH

Researchers used AI to indirectly compare data from three randomized controlled trials looking at sotatercept or selexipag in pulmonary arterial hypertension (PAH). Their findings suggest that sotater

Screening for PH in ILD

This study looked at how to better detect pulmonary hypertension (PH) in people with interstitial lung disease (ILD), since PH often makes breathing problems, quality of life, and survival worse. Rese

Comments